Table 14 Post-operative complications

Any complications

Gieger, 2016

68.0%

36.4%

0.001

Zhang X, 2014

13 (16.46%)

14 (45.16%)

0.002

Jing, 2014

8 (36.36%)

12 (44.44%)

ND

Granzow, 2013

7 (44%)

7 (39%)

1.0

Paydarfar, 2011

25 (75.75%)^a

10 (37.04%)^a

ND

Amarante, 2000

31%

0

Kroll, 1992

4 (13%)

17 (44%)

0.0145

Infection

Gieger, 2016

16.0%

7.3%

0.170

Granzow, 2013

0

1 (6.25%)

1.0

Mallet, 2009

4 (16%)

6 (13%)

1.0

Recipient site infection

Goyal, 2017

84 (14.3%)

19 (9.1%)

0.076

Kozin, 2016

2 (7.14%)^a

2 (4.44%)^a

0.106

Paydarfar, 2011

2 (6.06%)^a

2 (7.41%)^a

ND

O’Neil, 2010

4 (5.2%)

2 (5.4%)

0.962

Mallet, 2009

16% (4/25)

13% (6/45)

1.00

Chepeha, 2004

2 (3%)

18 (17%)

< 0.004

Donor site infection

Goyal, 2017

23 (3.9%)

5 (2.4%)

0.43

Kozin, 2016

3 (10.71%)^a

2 (4.44%)^a

0.106

O’Neil, 2010

1 (1.3%)

1 (2.7%)

0.593

Donor site morbidity

Chan Y, 2011

1(4.2%)

7(7.6%)

ND

2(2.3%)

ND

Fistula

Goyal, 2017

18 (3.1%)

17 (8.2%)

0.005

Geiger, 2016

22.0%

7.3%

0.039

Jing, 2014

5 (22.72%)^a

6 (22.22%)^a

ND

Paydarfar, 2011

5 (15.15%)^a

0

ND

Chan Y, 2011

3 (12.5%)

22 (23.9%)

ND

4 (4.6%)

ND

O’Neil, 2010

2/77 (2.6)

3/37 (8.1)

0.179

Demirtas, 2010

0

1 (12.5%)^a

ND

Mallet, 2009

2 (8%)

4 (9%)

1.00

Smeele, 2006

3 (0.09%)^a

1 (0.03%)^a

ND

Chepeha, 2004

4 (5%)

5 (5%)

0.74

Amarante, 2000

0

14 (20.59%)^a

ND

Abscess

Gieger, 2016

4.0%

7.3%

0.477

Dehiscence recipient or donor site

Gieger, 2016

44.0%

23.6%

0.029

Jing, 2014

1 (4.55%)^a

0

ND

O’Neil, 2010

2 (2.6%)

1 (2.7%)

0.974

Smeele, 2006

4 (12.5%)^a

1 (1.47%)^a

ND

Dehiscence recipient site

Kozin, 2016

4 (14.29%)^a

6 (13.33%)^a

NS

Granzow, 2013

0

1 (5.55%)^a

1.0

Paydarfar, 2011

5 (15.15%)^a

0

ND

Smeele, 2006

1 (3.13%)^a

1 (3.13%)^a

ND

Chepeha, 2004

0

11 (10%)

< 0.008

Dehiscence donor site

Kozin, 2016

0

4 (8.89%)^a

NS

Zhang S, 2015

1 (6.67%)^a

0

ND

Granzow, 2013

3 (18.75%)^a

2 (11.11%)^a

0.6

Paydarfar, 2011

0

2 (9.09%)^a

ND

Smeele, 2006

3 (9.38%)^a

0

ND

Kozin, 2016

3 (10.71%)^a

0

NS

Jing, 2014

0

4 (14.81%)^a

ND

Granzow, 2013

0

0

1.0

Demirtas, 2010

1 (8.33%)^a

0

ND

Hematoma

Chepeha, 2004

4 (6%)

4 (4%)

0.70

O’Neil, 2010

1 (1.3%)

1 (2.7%)

0.593

Hematoma Donor site

Howard, 2016

1 (11.11%)^a

1 (6.25%)^a

ND

0

ND

Smeele, 2006

0

1 (3.13%)^a

ND

Hematoma recipient site

Paydarfar, 2011

2 (6.06%)^a

2 (9.09%)^a

ND

Smeele, 2006

1 (3.13%)^a

1 (3.13%)^a

ND

Partial flap necrosis

Zhang S, 2015

0

2 (16.67%)^a

ND

Paydarfar, 2011

0

3 (13.64%)^a

ND

Smeele, 2006

1 (3.125%)^a

2 (6.25%)^a

NS

Chepeha, 2004

2 (2.82%)^a

12 (11%)^a

< 0.006

Amarante, 2000

0

11 (16.2%)^a

ND

Kroll, 1992

0

4 (10%)

0.1979

Total flap necrosis

Smeele, 2006

2 (6.25%)^a

1 (3.125%)^a

Amarante, 2000

3 (6.12%)^a

1 (1.5%)^a

ND

Partial or total flap necrosis

Mallet, 2009

1 (4%)

14 (31%)

0.02

Osteonecrosis

Goyal, 2017

36 (6.1%)

17 (8.2%)

0.33

Gieger, 2016

24.0%

3.6%

0.007

Deep Vein Thrombosis (Inferious member)

Sinha, 2017

1.6%

2.2%

0.2775

O’Neil, 2010

3 (3.9%)

1 (2.7%)

0.746

Venous obstruction (At site)

Paydarfar, 2011

1 (3.03%)^a

0

ND

Late anastomotic stricture

Chan Y, 2011

3 (12.5%)

25 (27.2%)

ND

2 (2.3%)

ND

Blood transfusion

Deganello, 2013

3 (19%)

4 (20%)

0.96